Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
3.390
-0.160 (-4.51%)
At close: Jan 30, 2026, 4:00 PM EST
3.390
0.00 (0.00%)
After-hours: Jan 30, 2026, 7:44 PM EST
Esperion Therapeutics Employees
Esperion Therapeutics had 304 employees as of December 31, 2024. The number of employees increased by 64 or 26.67% compared to the previous year.
Employees
304
Change (1Y)
64
Growth (1Y)
26.67%
Revenue / Employee
$999,349
Profits / Employee
-$348,128
Market Cap
798.11M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 304 | 64 | 26.67% |
| Dec 31, 2023 | 240 | 41 | 20.60% |
| Dec 31, 2022 | 199 | -19 | -8.72% |
| Dec 31, 2021 | 218 | -261 | -54.49% |
| Dec 31, 2020 | 479 | 286 | 148.19% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Evotec SE | 4,788 |
| Tilray Brands | 2,842 |
| Amphastar Pharmaceuticals | 2,028 |
| Emergent BioSolutions | 900 |
| Organogenesis Holdings | 869 |
| Pacira BioSciences | 790 |
| Cronos Group | 459 |
| Kamada | 420 |
ESPR News
- 18 days ago - Esperion Therapeutics, Inc. (ESPR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 21 days ago - Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Esperion Therapeutics, Inc. (ESPR) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 2 months ago - Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease - GlobeNewsWire
- 2 months ago - Wasatch Ultra Growth Fund Q3 2025 Top Contributors And Detractors - Seeking Alpha
- 2 months ago - Esperion Therapeutics, Inc. (ESPR) Discusses Breaking the Statin Intolerance Barrier and Closing the Care Gap in Cardiovascular Health Transcript - Seeking Alpha
- 2 months ago - Esperion Therapeutics: Still An Attractive Risk/Reward Narrative As The Earnings Clock Ticks Toward Profitability - Seeking Alpha